Cleveland-based Cervilenz has added to its Series A round, closing the round with $8.35 million. The company, backed by investors including Arboretum Ventures and Chrysalis Ventures, plans to use the funding to continue commercialization of its medical devices for women. The device is designed to predict the risk of preterm birth in pregnant women.

Related posts:

  1. CerviLenz Raises $4 Million
  2. PDC Biotech Raises €4 Million
  3. OrthoSensor Inks $21M Series B
  4. Valeritas Lands $150M Series C
  5. ALung Technologies Closes Series A Financing Round At $14 Million